Back to articles

Survival Doubled: Elraglusib Breakthrough Ignites Hope in Pancreatic Cancer Fight!

Caleb Wilson•Jun 2, 2025
A dramatic side-by-side comparison graph showing two survival curves: one for Elraglusib+GnP in a bold, ascending trajectory reaching 44.1% at 12 months, and another, much lower curve for GnP alone at 22.3%, clearly highlighting the "doubling" effect against a backdrop suggesting medical innovation.
  • Lifeline Extended: Elraglusib plus chemotherapy significantly boosts median overall survival by nearly three months in deadly metastatic pancreatic cancer.
  • One-Year Survival Soars: The combination therapy doubled the 12-month survival rate from 22.3% to an astounding 44.1%.
  • Hope on the Horizon: Actuate Therapeutics plans urgent talks with FDA/EMA, aiming to bring this first-in-class therapy to patients.

In the grim landscape of metastatic pancreatic ductal adenocarcinoma (mPDAC), a notoriously aggressive cancer with a five-year survival rate hovering around a bleak 10%4, a powerful new light has just been switched on. Actuate Therapeutics (NASDAQ: ACTU) electrified the ASCO 2025 Annual Meeting with stunning topline results from their Phase 2 trial of Elraglusib, a pioneering GSK-3β inhibitor1, 2, 7, 8.

The data from the Actuate-1801 Part 3B study is nothing short of revolutionary for a disease starved of major advancements. When Elraglusib was added to standard gemcitabine/nab-paclitaxel (GnP) chemotherapy, it slashed the risk of death by a remarkable 37% (HR=0.63, p=0.01). Median overall survival jumped to 10.1 months, a significant gain from 7.2 months with GnP alone. Most strikingly, the 12-month survival rate for patients receiving Elraglusib doubled, rocketing to 44.1% compared to 22.3% for those on chemotherapy alone2, 8.

"We significantly improved mOS, cut the risk of death by 37%, and doubled the 12-month survival rate," declared Daniel Schmitt, President & CEO of Actuate. "These results reinforce the transformative potential of our GSK-3β inhibitor program."

Dr. Deva Mahalingam, lead investigator from Northwestern University Feinberg School of Medicine, added, "The addition of elraglusib...is promising and may represent a meaningful therapeutic advance for patients with pancreatic cancer.”

With a manageable safety profile, despite some increased but manageable toxicities like high-grade neutropenia and low-grade visual disturbances2, Actuate is now poised to engage with regulatory authorities like the FDA in the latter half of 2025, driven by the urgent unmet need8. This breakthrough offers profound new hope to patients and families grappling with this devastating disease.

References

  1. www.onclive.com
  2. www.targetedonc.com
  3. www.onclive.com
  4. meetings.asco.org
  5. www.cancernetwork.com
  6. dailynews.ascopubs.org
  7. actuatetherapeutics.com
  8. actuatetherapeutics.com

Stay Updated!

Get the latest biotech and pharma news delivered to your inbox.